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Abstract
Background
There are limited data on the epidemiology, diagnosis and optimal management of nontu-
berculous mycobacterial (NTM) disease in children.
Methods
Retrospective cohort study of NTM cases over a 10-year-period at a tertiary referral hospital
in Australia.
Results
A total of 140 children with NTM disease, including 107 with lymphadenitis and 25 with skin
and soft tissue infections (SSTIs), were identified. The estimated incidence of NTM disease
was 0.6–1.6 cases / 100,000 children / year; no increasing trend was observed over the
study period. Temporal analyses revealed a seasonal incidence cycle around 12 months,
with peaks in late winter/spring and troughs in autumn. Mycobacterium-avium-complex
accounted for most cases (77.8%), followed byMycobacterium ulcerans (14.4%) and
Mycobacterium marinum (3.3%). Polymerase chain reaction testing had higher sensitivity
than culture and microscopy for acid-fast bacilli (92.0%, 67.2% and 35.7%, respectively).
The majority of lymphadenitis cases underwent surgical excision (97.2%); multiple recur-
rences in this group were less common in cases treated with clarithromycin and rifampicin
compared with clarithromycin alone or no anti-mycobacterial drugs (0% versus 7.1%;
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OR:0.73). SSTI recurrences were also less common in cases treated with two anti-myco-
bacterial drugs compared with one or none (10.5% versus 33.3%; OR:0.23).
Conclusions
There was seasonal variation in the incidence of NTM disease, analogous to recently pub-
lished observations in tuberculosis, which have been linked to seasonal variation in vitamin
D. Our finding that anti-mycobacterial combination therapy was associated with a reduced
risk of recurrences in patients with NTM lymphadenitis or SSTI requires further confirmation
in prospective trials.
Introduction
Currently there are more than 140 recognized species of nontuberculous mycobacteria (NTM).
[1] NTM can cause a broad range of infections in humans, including lymphadenitis, skin and
soft tissue infections (SSTIs), pulmonary disease, otitis media, and osteomyelitis [1]. The over-
all incidence of NTM disease increased significantly in the 1980s and 1990s, in parallel with the
rise of AIDS cases [1,2]. Data suggest the incidence of NTM disease in immunocompetent indi-
viduals has also risen over recent decades, although it remains unclear whether this represents
a true increase or reflects increased awareness and/or improvements in diagnostic methods
[1,3,4].
Despite the description of NTM disease in humans in the 1930s [5], there remains a surpris-
ing paucity of data in children. The vast majority of previous reports are case series or studies
that included fewer than 50 cases, which frequently lacked detail on the diagnostic workup,
management (especially anti-mycobacterial treatment) and outcome [1]. Consequently, there
remains considerable uncertainty about the optimal management of NTM disease in children,
as highlighted in the latest American Thoracic Society (ATS) / Infectious Diseases Society of
America (IDSA) statement [6].
This study aimed to determine the epidemiology, spectrum of disease, accuracy of diagnos-
tic methods, treatment and outcome in a large cohort of children with NTM disease at the larg-
est pediatric tertiary referral hospital in Australia.
Patients and Methods
Case definitions
NTM lymphadenitis and SSTIs were defined as i) isolation of NTM in culture, ii) detection of
NTM by polymerase chain reaction (PCR), or iii) presence of acid-fast bacilli in conjunction
with caseating or non-caseating granulomata on histological examination of the relevant tissue
(ie lymph node aspirate/tissue sample or skin/soft tissue sample, respectively) in the absence of
risk factors for tuberculosis (TB). Pulmonary NTM disease was defined according to the latest
ATS/IDSA statement on NTM infections [6]. Other forms of NTM disease were defined as iso-
lation of NTM in culture or detection by PCR in a sample from a normally sterile site or body
fluid.
Patients and data collection
Potential cases (aged 0–18 years) between September 2000 and September 2010 were identified
from the databases of the Histopathology and the Microbiology Departments of the Royal
NTMDisease in Children
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Children’s Hospital Melbourne (RCH), and from the database of the Victorian Infectious Dis-
eases Reference Laboratory (VIDRL). The former was searched for reports that included the
keyword ‘granuloma’; the latter two for positive mycobacterial culture and PCR results. The
RCH provides healthcare for a population of approximately 1.19 million children and adoles-
cents in the state of Victoria, Australia based on official 2006 census data [7]. Data were
extracted from laboratory and medical records into standardized data collection sheets.
Laboratory methods
Samples were routinely processed at the RCHMicrobiology Department, which performed
mycobacterial cultures and referred isolates to VIDRL for identification, which was done by
use of phenotypic methods, or 16S rRNA gene or internal transcribed spacer region sequencing
if the former produced no definitive result. PCRs were also performed at VIDRL, using a real-
time TaqMan (Roche Molecular Diagnostics, Castle Hill, Australia) PCR forMycobacterium
ulcerans that targets a multi-copy insertion sequence, as previously described [8]; other NTM
were identified by a generic mycobacterial PCR that amplifies the single copy 16S-23S inter-
genic spacer region, followed by species determination by restriction fragment length polymor-
phism or sequencing, as previously described [9]. QuantiFERON-TB Gold (QFT) assays were
performed at VIDRL according to manufacturer’s instructions.
Statistical analysis
The data were analyzed with STATA (StataCorp; College Station, TX, US) and Prism (Graph-
Pad; La Jolla, CA, US). For comparisons of two groups, MannWhitney U and two-tailed Fish-
er’s exact tests were used for the analysis of continuous and categorical data, respectively. For
comparisons of multiple groups, Kruskal Wallis and chi-square tests were used, as appropriate.
Incidence estimates were based on official census data using the child and adolescent popula-
tion figure from 2006 (1.19 million) as the denominator. Disease seasonality was analyzed
using discrete and continuous wavelet transform methods built into R software (Free Software
Foundation; Boston, MA, US), following detrending and denoising of the data [10]. Trend was
removed by subtracting the monthly estimated mean obtained from a trend regression (where
the independent variable was the number of cases/month, and the dependent variable was the
time in months). Denoising was performed using a discrete wavelet transform with Daubechies
length 6 wavelet filter.
Ethical approval
This study was approved by the Royal Children’s Hospital Melbourne Human Research Ethics
Committee (HREC Approval No. 31053). The HREC did not require consent to be obtained
from patients/carers due to the retrospective nature of the research project. All data were anon-
ymized and de-identified prior to analysis.
Results
A total of 140 children with NTM disease, comprising 107 cases of lymphadenitis, 25 cases of
SSTIs and 8 cases with other types of infections were identified. Demographic details and labo-
ratory results at presentation are shown in Table 1.
Annual case numbers varied between 7 per year (in 2009) and 19 per year (in 2004), corre-
sponding to an estimated incidence of NTM disease of 0.6 to 1.6 cases per 100,000 children per
year; no increasing trend was observed over the study period. Fig 1 shows the seasonal distribu-
tion of cases with NTM lymphadenitis and SSTIs. The highest number of cases occurred in
NTMDisease in Children
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spring and late winter, respectively. In both groups the lowest number of cases occurred around
March (autumn in the Southern hemisphere).
The denoising of the time series of NTM lymphadenitis and SSTI cases combined showed
the presence of intra-annual and inter-annual cycles (Fig 2). The level with highest peak signal-
to-noise ratio was the 3rd denoised level, which contained peaks generally collocated at the end
of each calendar year (spring in the Southern hemisphere; Fig 2, upper plot). The subsequent
analysis of these cycles using continuous wavelet transform found the occurrence of significant
(p<0.05) cycles ranging from 7 to 16 months, with those between 9 and 12 months spanning
the majority of the time series (Fig 3).
NTM lymphadenitis
Among the 107 cases of NTM lymphadenitis, in 92 cases (86.0%) the lymphadenitis affected
the submandibular or cervical area, in 8 (7.5%) the preauricular, in 6 (5.6%) the inguinal, and
in 1 (0.9%) the axillary area. In the majority of cases, inflammatory parameters were normal or
only mildly elevated (Table 1). Local symptoms and signs of infection at presentation com-
prised erythema in 73.4% (58/79), discoloration of the skin in 15.2% (12/79), swelling in 95.0%
(77/81), pain in 20.0% (16/80), tenderness in 30.4% (24/79), fluctuation in 16.7% (13/78), and
fistula formation in 2.5% (2/79). Constitutional symptoms at presentation are summarized in
Table 1. None of the cases of NTM lymphadenitis had a known underlying immunodeficiency;
one had type 1 diabetes mellitus.
The results of investigations for mycobacterial infections are summarized in Table 2. Only
few cases underwent a tuberculin skin test (TST) or a QFT assay. Polymerase-chain-reaction
(PCR) testing of lymph node material had the highest diagnostic yield (91.3% sensitivity), fol-
lowed by mycobacterial culture (64.8% sensitivity) and microscopy for acid-fast bacilli (30.3%
Table 1. Demographic characteristics, symptoms, and laboratory findings at presentation in the three groups with nontuberculousmycobacterial
disease.
NTM all cases
(n = 140)
NTM lymphadenitis
(n = 107)
NTM skin & soft tissue
infections (n = 25)
NTM other sites of
infection(n = 8)
p-value *
Age at presentation,
median (IQR)
2.8 (2.1–5.5) 2.6 (2.1–3.8) 8.9 (4.5–12.6) 5.5 (2.2–12.0) < 0.0001
Male gender, no. (%) 66/140 (47.1%) 48/107 (44.9%) 14/25 (56.0%) 4/8 (50.0%) 0.5954
Born overseas, no. (%) 4/105 (3.8%) 3/84 (3.6%) 1/15 (6.7%) 0/6 (0.0%) 0.7465
Constitutional symptoms
Fever, no. (%) 18/126 (14.3%) 12/94 (12.8%) 2/24 (8.3%) 4/8 (50.0%) 0.0100
Malaise, no. (%) 12/126 (9.5%) 8/94 (8.5%) 2/24 (8.3%) 2/8 (25.0%) 0.3050
Weight loss, no. (%) 4/126 (3.2%) 2/94 (2.1%) 0/24 (0.0%) 2/8 (25.0%) 0.0012
Night sweats, no. (%) 4/126 (3.2%) 3/94 (3.2%) 1/24 (4.2%) 0/8 (0.0%) 0.8440
Laboratory results
WBC, median (IQR) 9.5 (7.8–12.1) 9.6 (7.7–12.2) 8.4 (6.9–10.3) 11.7 (8.8–14.7) 0.0982
Neutrophil count, median
(IQR)
4.3 (3.3–6.7) 4.3 (3.0–6.7) 4.3 (3.6–5.6) 3.9 (2.7–9.4) 0.9969
Lymphocyte count, median
(IQR)
3.8 (2.3–5.2) 3.8 (2.9–5.6) 3.3 (2.1–4.9) 4.0 (1.7–6.9) 0.3443
CRP, median (IQR) 8.0 (8.0–25.0) 8.0 (8.0–31.0) 8.0 (8.0–12.3) 8.0 (5.5–30.0) 0.3876
ESR, median (IQR) 12.5 (8.3–31.5) 10.0 (7.8–30.5) 12.5 (5.8–39.3) 21.5 (17.8–65.0) 0.2285
* Three-group comparison of continuous variables with Kruskal Wallis test or of categorical variables with chi-square test.
Abbreviations used: IQR = interquartile range; no. = number; NTM = nontuberculous mycobacteria.
doi:10.1371/journal.pone.0147513.t001
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sensitivity).Mycobacterium avium complex (MAC) accounted for all but one of the 62 cases in
which a microbiological diagnosis was established at species level (Table 2).
Almost all cases (97.2%; 104/107) underwent complete surgical excision of the affected
lymph node or group of lymph nodes. Two cases (1.9%) underwent diagnostic biopsies only;
the remaining case (0.9%) had a partial excision. Eight patients (7.5%) developed facial palsy as
a complication of surgery; all these cases had submandibular or cervical lymphadenitis. Overall,
14 of the 107 cases received a course of anti-mycobacterial treatment post-operatively (dura-
tion ranging from 2–6 months), either with clarithromycin alone (42.9%) or a combination of
clarithromycin and rifampicin (57.1%). None of the cases experienced significant adverse
events related to anti-mycobacterial treatment; only one reported transient arthralgia. Four of
the cases (28.5%) treated with anti-mycobacterial drugs developed one or more recurrences,
compared with 15 cases (16.1%) which did not receive anti-mycobacterial treatment
(p = 0.2687). Of the 19 cases with recurrence, 16 underwent further surgical intervention.
Seven cases had between 2 and 4 more recurrences; none of those cases had received combina-
tion treatment with clarithromycin and rifampicin (ie2 recurrences in 0/8 cases (0%) treated
with clarithromycin and rifampicin versus 7/99 cases (7.1%) without anti-mycobacterial treat-
ment or clarithromycin only; odds ratio (OR) 0.73; p = 0.6053). In all patients, symptomatic
cure was achieved within 6 months of treatment initiation.
Fig 1. Seasonal distribution of nontuberculousmycobacterial lymphadenitis and skin and soft tissue infections over the study period according
to the month of initial presentation.
doi:10.1371/journal.pone.0147513.g001
NTMDisease in Children
PLOS ONE | DOI:10.1371/journal.pone.0147513 January 26, 2016 5 / 14
Fig 2. Time series of nontuberculousmycobacterial lymphadenitis and skin and soft tissue infections combined over the study period. The lower
plot shows the raw data; the upper plot shows the 3rd level denoised data. Denoising was performed using a discrete wavelet transform with Daubechies
length 6 wavelet filter.
doi:10.1371/journal.pone.0147513.g002
NTMDisease in Children
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NTM skin and soft tissue infections
Among the 25 cases of NTM SSTIs, the most commonly involved location was a lower limb
(52.0%), followed by an upper limb (28.0%), the face (12.0%), the ear (4.0%) and the scalp
(4.0%). In the majority of cases inflammatory parameters were normal or only mildly elevated
(Table 1). Local symptoms and signs of infection comprised erythema in 69.6% (16/23), discol-
oration in 30.4% (7/23), pain in 30.4% (7/23), and tenderness in 56.5% (13/23). Eighteen cases
(78.2%) had cutaneous ulceration; only one (4.3%) had co-existing regional lymphadenopathy.
Fig 3. Power spectrum obtained from a continuous wavelet transform based on a Morlet wavelet filter for the detrended and denoised time series
of nontuberculousmycobacterial lymphadenitis and skin and soft tissue infection cases combined. The graph shows the power for each period or
cycle (y-axis) along the time series (x-axis). High values are shown in dark-red and low values in dark-blue. The dark line contains the statistically significant
periods (p<0.05); the white line is the cone of influence that delimits the area not influenced by edge-effects.
doi:10.1371/journal.pone.0147513.g003
NTMDisease in Children
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The constitutional symptoms at presentation are shown in Table 1. Only one of the cases had a
known immunodeficiency (isolated IgE deficiency).
The results of investigations for mycobacterial infections are summarized in Table 2. Only
few cases had a TST or a QFT assay performed. Notably, one patient withMycobacterium mar-
inum infection had a positive QFT result, as described in an earlier publication [11]. PCR test-
ing of tissue had the highest diagnostic yield (91.3% sensitivity), followed by mycobacterial
culture (65.0% sensitivity) and microscopy for acid-fast bacilli (56.5% sensitivity).Mycobacte-
rium ulcerans accounted for almost two-thirds of the 20 cases in which a microbiological diag-
nosis was established at species level (Table 2).
Seventeen cases (68.0%) underwent complete surgical excision, 6 (24.0%) partial excision
for diagnostic purposes, and 2 (8.0%) biopsy only. Of the cases which underwent surgical exci-
sion, 12 received a course of anti-mycobacterial treatment post-operatively (duration ranging
from 1.5–6 months). The most common regimen was a combination of rifampicin and clari-
thromycin, used in 8 cases; one case each received a combination of rifampicin and erythromy-
cin, rifampicin monotherapy, clarithromycin monotherapy and triple therapy with rifampicin,
clarithromycin and ciprofloxacin. All 8 cases which did not undergo surgical excision received
anti-mycobacterial treatment (duration ranging from 3–6 months); 7 of those cases received a
combination of rifampicin and clarithromycin; one case (withM.marinum infection) received
a combination of rifampicin and ethambutol. None of the cases which received anti-mycobac-
terial treatment had significant adverse events; two cases had transient diarrhea.
Table 2. Results of diagnostic tests for mycobacterial infection, causative species and outcome in the three groups with nontuberculousmyco-
bacterial disease.
NTM all cases
(n = 140)
NTM lymphadenitis
(n = 107)
NTM skin & soft tissue
infections (n = 25)
NTM other sites of
infection (n = 8)
p-value *
Diagnostic tests
Positive TST, no. (%) ** 2/11 (18.4%) 1/7 (14.3%) 0/1 (0.0%) 1/3 (33.3%) 0.6850
Positive QFT, no. (%) 1/12 (8.3%) 0/6 (0.0%) 1/2 § (50.0%) 0/4 (0.0%) 0.0654
Positive stain for acid-fast
bacilli,no. (%)
46/129 (35.7%) 30/99 (30.3%) 13/23 (56.5%) 3/7 (42.9%) 0.0562
Positive culture, no. (%) 80/119 (67.2%) 59/91 (64.8%) 13/20 (65.0%) 8/8 (100.0%) 0.1236
Positive PCR, no. (%) 92/100 (92.0%) 63/69 (91.3%) 21/23 (91.3%) 8/8 (100.0%) 0.6852
Causative species
MAC, no. (%) 71 (78.9%) 61 (98.4%) 3 (15.0%) 7 (87.5%) -
M. ulcerans, no. (%) 13 (14.4%) - 13 (65.0%) - -
M. marinum, no. (%) 3 (3.3%) - 3 (15.0%) - -
M. simae, no. (%) 1 (1.1%) 1 (1.6%) - - -
M. ﬂavescens, no. (%) 1 (1.1%) - 1 (5.0%) - -
M. terrae, no. (%) 1 (1.1%) - - 1 (12.5%) -
Outcome
Symptomatic cure at 6
months, no. (%)
122/123 (99.2%) 92/92 (100%) 24/24 (100%) 7/8 (87.5%) 0.0007
Recurrence, no. (%) 25/139 (18.0%) 19/107 (17.8%) 4/24 (16.7%) 0/8 (0.0%) 0.4010
* Three-group comparison of continuous variables with Kruskal Wallis test or of categorical variables with chi-square test.
** Positive TST deﬁned as induration of 10 mm at 48 to 72 hours.
§ The patient with the positive QFT result had Mycobacterium marinum infection.
Abbreviations used: IQR = interquartile range; no. = number; NTM = nontuberculous mycobacteria; PCR = polymerase chain reaction;
QFT = QuantiFERON-TB Gold assay; TST = tuberculin skin test.
doi:10.1371/journal.pone.0147513.t002
NTMDisease in Children
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Four cases, all of which had previously undergone surgical excision, had a recurrence; three
of these underwent further surgical intervention. Two of these cases had received a regimen
comprising two anti-mycobacterial drugs, while one had received clarithromycin only and the
remaining one no anti-mycobacterial treatment (ie recurrence in 2/19 cases (10.5%) treated
with two or more anti-mycobacterial drugs versus 2/6 (33.3%) treated with one anti-mycobac-
terial drug or none; OR 0.23; p = 0.2340). All cases were reported to be cured at 6 months after
treatment initiation.
NTM infections affecting other sites
Eight patients had other types of NTM disease, comprising 5 cases with pulmonary infection,
and one case each of genitourinary, retropharyngeal and disseminated infection. Demographic
details and laboratory results at presentation are shown in Table 1. The results of investigations
for mycobacterial infections are summarized in Table 2. Only one case, a patient with pulmo-
nary MAC infection, had a positive TST result.
The cases with pulmonary disease comprised 4 cases with MAC infection and one with
Mycobacterium terrae infection. Underlying conditions were present in two cases; one had
mannose-binding lection deficiency (M. terrae infection) and one had cystic fibrosis (MAC
infection). All five cases had abnormal chest x-rays at presentation. Respiratory symptoms at
presentation comprised cough (100%), wheeze (60%), and shortness of breath (40%). The
duration of anti-mycobacterial treatment varied between 6 months and 3.5 years. In four cases
symptomatic cure was achieved at the end of treatment; the patient withM. terrae infection
showed little improvement after 3.5 years of treatment.
The case with retropharyngeal infection was a 2-year-old, who presented with signs of
upper airway obstruction and apneas. A computer-tomography scan revealed retropharyngeal
lymphadenopathy. Histology of biopsy tissue showed granulomatous inflammation; MAC was
detected by PCR. The patient was treated with rifampicin and erythromycin for 6 months, and
made a full recovery.
The case with genitourinary infection was a 5-year-old oncology patient who initially pre-
sented with febrile neutropenia. MAC was repeatedly cultured from urine, and PCR tests also
confirmed MAC infection. She was successfully treated with a 10-month-course of clarithro-
mycin, ciprofloxacin and ethambutol.
The patient with disseminated MAC infection was a 3-year-old boy with interferon-gamma
receptor deficiency, who presented with multifocal osteomyelitis. A biopsy from a rib revealed
caseating granulomata on histology; MAC was detected by PCR. He was treated with clarithro-
mycin, rifampicin and ethambutol, and made a full recovery.
Discussion
To our knowledge this is the largest study of NTM infections in children published to date. In
accordance with data from a variety of geographical locations, our findings suggest that NTM
disease remains uncommon [1,12–14]. Notably, our estimated incidence of 0.6 to 1.6 cases per
100,000 children per year is remarkably similar to estimates reported by recent studies in
Europe [12,13]. Although a few studies have reported a rise in NTM disease in the last two
decades, we did not observe an increasing trend [15–17].
We believe our study is the first to describe a seasonal variation in the incidence of NTM
disease, with the lowest incidence occurring in autumn and the highest in late winter to spring,
with inter-annual cycles typically ranging from 9 to 12 months. This observation is intriguing
in light of recent reports of a seasonal variation in the incidence of TB disease [18–20]. In
accordance with our findings in NTM disease, most of these studies reported that the incidence
NTMDisease in Children
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of TB peaked in spring, while the lowest incidence was observed in autumn [18,19]. Although
the underlying mechanism for this seasonal pattern of TB remains uncertain, it has been postu-
lated that seasonal variation in vitamin D plays a role [18]. Average daily sunshine in Victoria
is highest in January and February (ie the months preceding March, when the lowest incidence
was observed; average daily sunshine: 8–10 hours), and lowest in June and July (ie the months
preceding the rise in case numbers; average daily sunshine: 4–6 hours) [21]. Interestingly, a
recent study showed that in the Australian population, 25-hydroxyvitamin D levels are on
average lowest in August and September followed by a slow increment over the following
months [22], which coincides with the time period when the highest numbers of cases of NTM
disease were observed our study. There is considerable evidence supporting the notion that
vitamin D plays an important part in the immune response to TB [23]. However, only a few
studies have reported an association between vitamin D deficiency or vitamin D receptor gene
polymorphism and NTM disease [24,25].
Lymphadenitis accounted for the clear majority of cases of NTM diseases in our study, con-
sistent with studies in other geographical locations [13,14,26,27]. The comparatively high pro-
portion of NTM SSTIs is likely explained by the fact that major Australian epicenters ofM.
ulcerans infection extend to within 50 kilometers of our hospital. In Australia, the disease is
commonly referred to as ‘Bairnsdale ulcer’ (rather than ‘Buruli ulcer’) based on a report from
that area in 1948, which included the first description of the causative organism [28]. Our
study population included three cases ofM.marinum infection, despite only a few pediatric
cases being reported in the literature [11,29]. This likely relates to the fact that a large propor-
tion of the population served by our hospital lives in close proximity to coastal waters, and the
popularity of swimming and other watersports, which are significant risk factors forM.mari-
num infection [29].
NTM infections other than lymphadenitis and SSTIs accounted for only a small proportion
of cases. MAC was the most frequent cause of pulmonary NTM infection, in keeping with a
recent review of pulmonary NTM disease in immunocompetent children [30]. It has been sug-
gested that the incidence of pulmonary NTM disease is rising, particularly in patients with cys-
tic fibrosis [31,32]. Improved survival and selection of NTM through antibiotic pressure are
the likely explanation for the increase in this particular patient group [32].
Our study highlights the superiority of molecular methods over conventional culture for the
diagnosis of NTM disease. Only few cases had undergone testing with QFT assays, partly
because these were only licensed three years into the study period. However, the case withM.
marinum infection with a positive result highlights that a positive QFT assay can also occur in
infections with NTM species that express one or more of the stimulatory antigens used in this
assay (ie ESAT-6, CFP-10 and TB 7.7), which includesM.marinum,M. kansasii andM. szulgai
[11,33].
There remains widespread controversy regarding the optimal management of NTM lymph-
adenitis [34–36], primarily as a result of limited data. Most previous publications report small
cohorts, often treated with a myriad of anti-mycobacterial regimens. To date, only one ran-
domized controlled trial comparing surgical intervention and anti-mycobacterial treatment
has been published [37]. In that study, 100 children with cervicofacial NTM lymphadenitis
were randomized to surgical excision or conservative therapy with a regimen of clarithromycin
and rifabutin. Cure at 6 months (as defined by the authors) was achieved in 96% of the surgical
compared with 66% in the conservative treatment group, leading the authors to conclude that
surgical treatment was superior. However, a number of aspects complicate the interpretation of
the study findings. Firstly, patients underwent diagnostic fine needle aspiration prior to ran-
domization, a procedure associated with fistula formation and poor healing [1,38], which likely
disadvantaged the conservative treatment group. Secondly, in that group, three of the NTM
NTMDisease in Children
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isolates were found to be resistant to clarithromycin, and a further three resistant to rifabutin.
Finally, patients in the conservative treatment arm who showed no improvement at the
3-month-review were classified as ‘treatment failure’ and subjected to surgery, rather than
being continued on anti-mycobacterial therapy; this applied to 10 patients, which contributed
significantly to the total of 17 cases of ‘treatment failure’.
Surgical treatment of cervicofacial NTM lymphadenitis is associated with significant risks
[35]. Apart from the potential complications associated with general anaesthesia, well-chroni-
cled complications include post-operative wound infections, hematoma formation, and–most
importantly–facial palsy. In the aforementioned study, 28% of patients in the surgical treat-
ment arm had surgical complications, which included facial palsy in 14%, with one case (2%)
being permanent [37]. Our data compare favorably, with only 7.5% of patients who underwent
surgery for NTM lymphadenitis developing facial palsy. However, importantly, our data sug-
gest that in comparison the risks associated with conservative treatment are low, as none of the
patients who received anti-mycobacterial treatment experienced significant adverse events.
Our data do not clarify whether conservative treatment alone is a suitable alternative to sur-
gery, as almost all patients with NTM lymphadenitis underwent surgery. We found that the
proportion of patients with recurrence appeared to be higher in cases which received anti-
mycobacterial treatment (in addition to surgery). However, this is likely explained by the fact
that children with extensive disease and/or incomplete excision were more likely to have been
started on anti-mycobacterial treatment than those with less extensive disease (ie selection
bias). Interestingly, we found that multiple recurrences were less common in children who
were treated with a combination of clarithromycin and rifampicin compared with cases which
received clarithromycin only or no anti-mycobacterial treatment. These findings indicate that
in populations where the majority of NTM lymphadenitis is caused by MAC, adjunctive clari-
thromycin/rifampicin combination therapy may be beneficial for reducing the risk of multiple
recurrences.
The optimal treatment of NTM SSTIs also continues to be debated, again as a result of lim-
ited high-quality data. However, a recent randomized trial in patients withM. ulcerans infec-
tion showed that conservative treatment with two anti-mycobacterial drugs is successful in the
majority of cases with early limited disease [39]. Many experts recommend the use of a combi-
nation of two anti-mycobacterial drugs to treatM.marinum infections, although the data
regarding treatment of this species are less robust [29]. This is in accordance with the latest
ATS/IDSA statement, which highlights the limited evidence to support this particular recom-
mendation [6]. Although most of the patients with SSTIs in this study underwent surgery,
thereby precluding conclusions regarding the efficacy of conservative treatment alone, we
found that the proportion of patients experiencing a recurrence was considerably smaller in
the group of cases treated with two anti-mycobacterial drugs compared with those which
received only one anti-mycobacterial drug or none.
Limitations
The main limitation of this study lies in its retrospective nature, which resulted in some missing
data, mainly related to presenting symptoms and signs. However, all data relating to time of
presentation, treatment and outcome were complete, highlighting the robustness of the main
study findings. Our incidence estimates are based on census data from 2006 and the assump-
tion that the paediatric population in Victoria remained stable over the study period. This is
supported by official census data (available at: http://www.censusdata.abs.gov.au) showing that
between 2006 and 2011 there was only an approximate 5% increase in the number of Victorian
residents 0 to 14 years of age. Nevertheless, this approach may have resulted in minor
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imprecisions in our incidence estimates. Although our hospital is the largest paediatric referral
center in Victoria by far, it is possible that a small number of cases with NTM disease received
care elsewhere. Therefore, the true incidence of NTM disease may be higher than our estimates.
One further potential limitation is that the seasonal data are based on the time of presentation
to specialist services in our hospital, rather than the onset of the disease. However, the thresh-
old for referrals for a specialist opinion in our setting is low and waiting times are relatively
short; therefore significant delays between disease onset and assessment in the hospital are
uncommon.
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